Status
Please wait ...

Details for receptor: Tumor necrosis factor receptor superfamily member 11B

  • Top
  • General information
  • Subunits
    •
  • External resources
  • General information
  • Hormones
  • Anatomical structures
  • Click to access the toolbox
EndoNet ID: ENR01295

To link to the content of EndoNet use the EndoNet ID that is given on the detail pages in the format ENX0000, where X is a place holder for the type of the component (e. g. R for receptor or C for anatomical structure).
As URL for the linking append this ID to the detail page for this type of component.
For an hormone that would be: 

http://endonet.bioinf.med.uni-goettingen.de/hormone/ENH00000

It is also possible to use the search of EndoNet to link to the right detail page. The URL should look like 

http://endonet.bioinf.med.uni-goettingen.de/search/ENC00000
If the search pattern is unambigious the user is directed to the corresponding detail page.

Synonyms

  • Tumor necrosis factor receptor superfamily member 11B
  • Osteoclastogenesis inhibitory factor
  • OPG
  • Osteoprotegerin

General information

  • OPG is the inhibitor of osteoclastogenesis. [1]
  • Osteoprotegerin, a member of the TNF-receptor family expressed by osteoblasts, has documented effects on the regulation of bone metabolism. OPG inhibits bone resorption and binds with strong affinity to its ligand RANKL, thereby preventing RANKL from binding to its receptor RANK. This system is regulated by calcium-modifying hormones. OPG may also be pivotal in modulating the immune system. [2]
  • OPG also acts as an important regulatory molecule in the vasculature. [3]
  • Osteoprotegerin inhibits proliferation of myeloid progenitor cells. [4]
  • Osteoprotegerin (OPG) and decoy receptor 3 (DcR) are soluble members of the tumor necrosis factor receptor (TNFR) superfamily. [4]
  • OPG is an antiresorptive cytokine and a key regulator of osteoclastogenesis and activity. [5]
  • OPG is downregulated by glucocorticoids and cyclosporine A. [5]
  • OPG is a soluble "decoy" receptor for tumor necrosis factor-related apoptosis-inducing ligand and ligand of the receptor activator of NF-kappaB. [6]
  • OPG blocks endothelial cell apoptosis through binding to TRAIL, preventing the interaction with death-inducing TRAIAL-receptors. [7]

Links to other resources

UniProt O00300
Ensembl ENST00000297350

Subunit information

Osteoprotegerin mature peptide

Sequence 
PCPDHYYTD SWHTSDECL YCSPVCKEL 
QYVKQECNR THNRVCECK EGRYLEIEF 
CLKHRSCPP GFGVVQAGT PERNTVCKR 
CPDGFFSNE TSSKAPCRK HTNCSVFGL 
LLTQKGNAT HDNICSGNS ESTQKCGID 
VTLCEEAFF RFAVPTKFT PNWLSVLVD 
NLPGTKVNA ESVERIKRQ HSSQEQTFQ 
LLKLWKHQN KDQDIVKKI IQDIDLCEN 
SVQRHIGHA NLTFEQLRS LMESLPGKK 
VGAEDIEKT IKACKPSDQ ILKLLSLWR 
IKNGDQDTL KGLMHALKH SKTYHFPKT 
VTQSLKKTI RFLHSFTMY KLYQKLFLE 
MIGNQVQSV KISCL

Binding hormones

    Anatomical structures with this receptor

    • osteoblast

      Induced phenotypes

      • negative regulation of osteoclast differentiation
        • Tumor necrosis factor receptor superfamily member 11B specifically inhibits osteoclastogenesis in a dose-dependent manner elicited through three distinct signaling patways stimulated by 1alpha,25-dihydroxy vitamin D3, parathyroid hormone, and interleukin-11. [8]
      • Paget disease, juvenlie
        • Juvenile Paget disease can result from osteoprotegerin deficiency by homozygous or compound heterozygous mutation in the TNFRSF11B gene. [9]
    Reference